Isis Pharmaceuticals (IONS): יחס חוב לטווח ארוך להון

This GURU.Markets price chart illustrates the price action of Ionis Pharmaceuticals (IONS), whose strategy is based on licensing rights to pharmaceutical companies for a fee, ensuring high returns. The current indicator is 4.82. Currently, R&D centers are developing revolutionary therapies to combat heart and brain pathologies. Risks are minimized through a broad development pipeline and strategic collaborations with market leaders.

To assess the credit quality of Ionis Pharmaceuticals (IONS), the analyst utilizes the long-term financial leverage ratio, which compares liabilities with maturities exceeding one year against equity to determine the degree of reliance on borrowed funds. The stability of this metric is supported by an RNA drug diversification strategy and partnerships with pharma behemoths, which minimize the debt load and confirm the company's financial autonomy.